NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.
C-Rad AB (publ) ("C-RAD" or the "Company") publishes an addendum (the "Addendum ") to the prospectus regarding the invitation to subscribe for shares in C-RAD, which was approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the ”SFSA”) on April 28, 2016 and was published the same day (the "Prospectus"). The Addendum is a part of and shall be read together with the Prospectus.
The Addendum has been prepared due to the fact that C-RAD on May 9, 2016 published its interim report for the period January 1 to March 31, 2016.
The Addendum has been approved by the SFSA and will be available on SFSA’s website (www.fi.se), C-RAD’s website (www.c-rad.se) and Pareto Securities AB’s website (www.paretosec.com).
Investors who, prior to the publication of the Addendum, have subscribed for or in any other way has given their consent to purchase or to subscribe for shares under the Prospectus, have in accordance with Chapter 2, Section 34 of the Financial Instruments Trading Act (Sw. lag (1991:980) om handel med finansiella instrument) the right to withdraw submitted subscription or consent up to and including 13 May, 2016, i.e. within two business days from the publication of the Addendum. Withdrawal is made in writing to Pareto Securities, Issuer Service/C-Rad, Box 74 15, 103 91 Stockholm, Sweden. Investors who have subscribed for shares through a nominee shall contact their nominee regarding withdrawal. Subscriptions not withdrawn will remain binding and those who wish to remain as subscribers of shares do not need to take any actions. For full terms and additional information on the rights issue, please refer to the Prospectus. No changes in the timeline of the rights issue has been made due to the Addendum.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
IMPORTANT INFORMATION
This press release does not constitute an offer or invitation to acquire shares in C-RAD. Both the Prospectus and the Addendum relating to the rights issue have been approved and registered by the SFSA (Finansinspektionen) and are available on inter alia C-RAD’s website.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. C-RAD does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 43. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com
The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).
